IceCure Medical announced a 26% increase in global revenue for Q1 2026, driven by an 84% sales surge in North America and a 31% rise in U.S. sales following FDA clearance of its ProSense® cryoablation system for early-stage breast cancer. Active U.S. customer accounts using ProSense® grew 46%, reflecting strong adoption fueled by expanded reimbursement, clinical endorsements, and growing physician interest. The company plans to expand its U.S. sales footprint to eight regions and advance a post-marketing study to accelerate adoption. Despite increased R&D and administrative expenses, IceCure remains focused on commercial growth and clinical validation of its minimally invasive tumor treatment technology.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
SpaceX shares fell below their IPO price of $135 for the first time, dropping to $132.28 before closing slightly above at $135.27. The stock is down about 16% from its June 12 closing price and 36% from its peak on June 16. The decline reflects inves...
Latham Group is rated a Buy as it implements a new CEO-led strategy focusing on expanding its core market, increasing presence in the southern U.S., adopting automatic pool covers, and pursuing mergers and acquisitions. Despite challenges in the depr...
